Filing Flows › 8-K events › Peraso
Peraso: entry into a material definitive agreement
Form 8-K filed Oct 26, 2026 · items 1.01, 3.02, 7.01
Share offeringsPeraso Announces $10 Million Strategic Investment from Nant Capital to Accelerate Development and Commercialization of Advanced Drone Communications
What the filing says
On October 26, 2026, Peraso Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Nant Capital, LLC, an accredited investor (the “Purchaser”), pursuant to which the Company agreed to issue and sell to the Purchaser, and the Purchaser agreed to purchas
ScaleThe filing names $10.0M: about 191% of Peraso's annual revenue ($5.2M, four times the latest quarter), or 7.7 quarters of sales.
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 3.02: +0.1% next session across 2,750. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Peraso at a glance
Peraso, Q2 2026: revenue $1.3M (-41% year over year), operating margin -171.1%. The chart follows the revenue to costs, profit and cash.
Peraso: every quarter, Q/Q and Y/Y, holders and guidance →
Peraso’s other material 8-Ks
Other recent share offerings
- Airsculpt Technologies Nov 6, 2026
- Biovie Nov 6, 2026
- Clean Energy Technologies Nov 6, 2026
- Nextnrg Nov 6, 2026
- Paid Nov 6, 2026
- Silo Pharma Nov 6, 2026
- Agility Robotics Nov 6, 2026
- American Healthcare REIT Nov 6, 2026
- Entera Bio Nov 6, 2026
- Janus Living Nov 6, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.